Atossa Genetics Inc. (NASDAQ:ATOS) Short Interest Down 91.3% in February

Atossa Genetics Inc. (NASDAQ:ATOS) was the target of a significant decrease in short interest in February. As of February 13th, there was short interest totaling 408,724 shares, a decrease of 91.3% from the January 29th total of 4,696,759 shares. Approximately 5.2% of the shares of the company are short sold. Based on an average daily volume of 311,677 shares, the days-to-cover ratio is currently 1.3 days. Based on an average daily volume of 311,677 shares, the days-to-cover ratio is currently 1.3 days. Approximately 5.2% of the shares of the company are short sold.

Atossa Genetics Stock Performance

Shares of NASDAQ ATOS traded up $0.06 during midday trading on Wednesday, reaching $4.27. 78,373 shares of the company traded hands, compared to its average volume of 176,974. The firm has a market cap of $36.76 million, a PE ratio of -1.19 and a beta of 1.36. The stock’s 50-day simple moving average is $7.95 and its 200-day simple moving average is $10.98. Atossa Genetics has a 12 month low of $3.76 and a 12 month high of $19.35.

Wall Street Analysts Forecast Growth

ATOS has been the topic of a number of recent research reports. Ascendiant Capital Markets lifted their price target on shares of Atossa Genetics from $116.25 to $120.00 and gave the stock a “buy” rating in a research note on Monday, December 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Atossa Genetics in a report on Wednesday, January 21st. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $95.00.

Hedge Funds Weigh In On Atossa Genetics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ATOS. Bank of America Corp DE grew its stake in Atossa Genetics by 51.3% during the fourth quarter. Bank of America Corp DE now owns 111,475 shares of the company’s stock worth $105,000 after buying an additional 37,809 shares during the last quarter. Y Intercept Hong Kong Ltd acquired a new position in shares of Atossa Genetics in the 2nd quarter worth approximately $321,000. Catalyst Funds Management Pty Ltd bought a new stake in Atossa Genetics during the 2nd quarter worth approximately $49,000. Qube Research & Technologies Ltd grew its position in Atossa Genetics by 357.4% during the 2nd quarter. Qube Research & Technologies Ltd now owns 416,374 shares of the company’s stock worth $346,000 after acquiring an additional 325,340 shares during the last quarter. Finally, Jane Street Group LLC acquired a new stake in Atossa Genetics during the 2nd quarter valued at $381,000. 12.74% of the stock is currently owned by institutional investors and hedge funds.

About Atossa Genetics

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.